vimarsana.com

Oppenheimer reiterated their outperform rating on shares of Trevi Therapeutics (NASDAQ:TRVI – Free Report) in a report issued on Thursday morning, Benzinga reports. The brokerage currently has a $9.00 target price on the stock. Separately, Needham & Company LLC reaffirmed a buy rating and set a $8.00 price target on shares of Trevi Therapeutics in […]

Related Keywords

,Nuveen Asset Management ,Needham Company ,Vanguard Group Inc ,Trevi Therapeutics Inc ,Trevi Therapeutics ,Free Report ,Street Corp ,Asset Management ,Get Free Report ,Trevi Therapeutics Daily ,Nasdaq Trvi ,Trvi ,Medical ,Reiterated Rating ,Oppenheimer Holdings Inc ,

© 2024 Vimarsana

vimarsana.com © 2020. All Rights Reserved.